A new series of pET-derived vectors for high efficiency expression of Pseudomonas exotoxin-based fusion proteins
- PMID: 10095114
- DOI: 10.1016/s0378-1119(99)00038-4
A new series of pET-derived vectors for high efficiency expression of Pseudomonas exotoxin-based fusion proteins
Abstract
Recombinant immunotoxins (rITs) are highly specific anti-tumor agents composed of monoclonal antibody fragments or other specific carriers coupled to plant or bacterial toxins. A major problem in the purification of rITs is the low periplasmic yield in currently available expression systems. Thus, the aim of this study was the development of a new bacterial expression system for high-level production of rITs. We constructed a series of pET-based vectors for pelB-directed periplasmic secretion or cytoplasmic production under the control of the T7lac promoter. Expression in Escherichia coli BL21(DE3)pLysS allowed a tightly regulated isopropyl beta-d-thiogalactopyranoside (IPTG) induction of protein synthesis. An enterokinase-cleavable poly-histidine cluster was introduced into this setup for purification by affinity chromatography. A major modification resulted from the insertion of a specifically designed multiple cloning site. It contains only rare restriction enzyme recognition sites used for cloning of immunoglobulin variable region genes, as well as unique SfiI and NotI restriction sites for directed insertion of single-chain variable fragments (scFv) available from established bacteriophage systems. For this purpose, we deleted two naturally occurring internal SfiI consensus sites in a deletion mutant of Pseudomonas aeruginosa exotoxin A (ETA'). Each single structural element of the new vector (promoter, leader sequence, purification tag, scFv sequence, selectable marker, and toxin gene) was flanked by unique restriction sites allowing simple directional substitution. The fidelity of IPTG induction and high-level expression were demonstrated using an anti-CD30 scFv (Ki-4) fused to ETA'. These data confirm a bacterial vector system especially designed for efficient periplasmic expression of ETA'-based fusion toxins.
Similar articles
-
CD30L-ETA': a new recombinant immunotoxin based on the CD30 ligand for possible use against human lymphoma.Cytokines Cell Mol Ther. 1999 Jun;5(2):69-78. Cytokines Cell Mol Ther. 1999. PMID: 10515679
-
Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells.Cancer Res. 2003 Dec 1;63(23):8414-9. Cancer Res. 2003. PMID: 14679004
-
Optimization of expression and purification of two biologically active chimeric fusion proteins that consist of human interleukin-13 and Pseudomonas exotoxin in Escherichia coli.Protein Expr Purif. 2005 Feb;39(2):189-98. doi: 10.1016/j.pep.2004.10.012. Protein Expr Purif. 2005. PMID: 15642470
-
Recombinant immunotoxins for the treatment of Hodgkin's disease (Review).Int J Mol Med. 2000 Nov;6(5):509-14. doi: 10.3892/ijmm.6.5.509. Int J Mol Med. 2000. PMID: 11029515 Review.
-
Regulation of expression of Pseudomonas exotoxin A by iron.Methods Enzymol. 1994;235:502-17. doi: 10.1016/0076-6879(94)35166-x. Methods Enzymol. 1994. PMID: 8057922 Review. No abstract available.
Cited by
-
Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities.J Cancer Res Clin Oncol. 2015 Dec;141(12):2079-95. doi: 10.1007/s00432-015-1975-5. Epub 2015 Apr 22. J Cancer Res Clin Oncol. 2015. PMID: 25899161
-
Compatible-solute-supported periplasmic expression of functional recombinant proteins under stress conditions.Appl Environ Microbiol. 2000 Apr;66(4):1572-9. doi: 10.1128/AEM.66.4.1572-1579.2000. Appl Environ Microbiol. 2000. PMID: 10742244 Free PMC article.
-
In vivo imaging of immunotoxin treatment using Katushka-transfected A-431 cells in a murine xenograft tumour model.Cancer Immunol Immunother. 2012 Oct;61(10):1617-26. doi: 10.1007/s00262-012-1219-3. Epub 2012 Feb 19. Cancer Immunol Immunother. 2012. PMID: 22350071 Free PMC article.
-
Novel PSCA targeting scFv-fusion proteins for diagnosis and immunotherapy of prostate cancer.J Cancer Res Clin Oncol. 2017 Oct;143(10):2025-2038. doi: 10.1007/s00432-017-2472-9. Epub 2017 Jun 30. J Cancer Res Clin Oncol. 2017. PMID: 28667390
-
Novel fusion proteins for the antigen-specific staining and elimination of B cell receptor-positive cell populations demonstrated by a tetanus toxoid fragment C (TTC) model antigen.BMC Biotechnol. 2016 Feb 17;16:18. doi: 10.1186/s12896-016-0249-x. BMC Biotechnol. 2016. PMID: 26883813 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources